IDEAS home Printed from https://ideas.repec.org/a/spr/drugsa/v45y2022i12d10.1007_s40264-022-01246-4.html
   My bibliography  Save this article

Withdrawal Syndrome Following Discontinuation of 28 Antidepressants: Pharmacovigilance Analysis of 31,688 Reports from the WHO Spontaneous Reporting Database

Author

Listed:
  • Chiara Gastaldon

    (University of Verona)

  • Georgios Schoretsanitis

    (Northwell Health
    Zucker School of Medicine at Northwell/Hofstra
    University of Zurich)

  • Elena Arzenton

    (University of Verona)

  • Emanuel Raschi

    (University of Bologna)

  • Davide Papola

    (University of Verona)

  • Giovanni Ostuzzi

    (University of Verona)

  • Ugo Moretti

    (University of Verona)

  • Erich Seifritz

    (University of Zurich)

  • John M. Kane

    (Northwell Health
    Zucker School of Medicine at Northwell/Hofstra
    The Feinstein Institute for Medical Research)

  • Gianluca Trifirò

    (University of Verona)

  • Corrado Barbui

    (University of Verona)

Abstract

Introduction Evidence is lacking on withdrawal syndrome related to individual antidepressants and relevant risk factors for severe reactions. Objective To ascertain whether antidepressants are associated with an increased reporting of withdrawal syndrome as compared with other medications, and to investigate risk factors for severe reactions. Methods This is a case/non-case pharmacovigilance study, based on the VigiBase®, the WHO global database of individual case safety reports of suspected adverse drug reactions. We performed a disproportionality analysis of reports of antidepressant-related withdrawal syndrome (calculating reporting odds ratio [ROR] and Bayesian information component [IC]). We compared antidepressants to all other drugs, to buprenorphine (positive control), and to each other within each class of antidepressants (selective serotonin reuptake inhibitors [SSRIs], tricyclics and other antidepressants). Antidepressants with significant disproportionate reporting were ranked in terms of clinical priority. Serious versus non-serious reactions were compared. Results There were 31,688 reports of antidepressant-related withdrawal syndrome were found. A disproportionate reporting was detected for 23 antidepressants. The estimated ROR for antidepressants altogether, compared to all other drugs, was 14.26 (95% CI 14.08–14.45), 17.01 for other antidepressants (95% CI 16.73–17.29), 13.65 for SSRIs (95% CI 13.41–13.90) and 2.8 for tricyclics (95% CI 2.59–3.02). Based on clinical priority ranking, the strongest disproportionate reporting was found for paroxetine, duloxetine, venlafaxine and desvenlafaxine, being comparable to buprenorphine. Withdrawal syndrome was reported as severe more often in males, adolescents, persons in polypharmacy, and with a longer antidepressant treatment duration (p

Suggested Citation

  • Chiara Gastaldon & Georgios Schoretsanitis & Elena Arzenton & Emanuel Raschi & Davide Papola & Giovanni Ostuzzi & Ugo Moretti & Erich Seifritz & John M. Kane & Gianluca Trifirò & Corrado Barbui, 2022. "Withdrawal Syndrome Following Discontinuation of 28 Antidepressants: Pharmacovigilance Analysis of 31,688 Reports from the WHO Spontaneous Reporting Database," Drug Safety, Springer, vol. 45(12), pages 1539-1549, December.
    • Handle: RePEc:spr:drugsa:v:45:y:2022:i:12:d:10.1007_s40264-022-01246-4
    DOI: 10.1007/s40264-022-01246-4
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40264-022-01246-4
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40264-022-01246-4?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:45:y:2022:i:12:d:10.1007_s40264-022-01246-4. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.